Thanks for a well argued and valuable contribution I was...

Thanks for a well argued and valuable contribution I was actually hoping someone would provide a well argued rebuttal.

I believe Clarity had just completed their COBRA study which had detected a high number of lesions which were undetectable using existing SOC psma scans. However under the terms of the FDA protocol if the lesion wasn't biopsied and it wasn't visible using follow up SOC psma scans it was deemed a false positive.
So correct me if I'm mistaken but Clarity now faces the challenge of having to prove the lesions detected are not false positives by biopsy against the current SOC which was created and now determined by Illucix, Pylarify etc.

Now if these conditions have changed by the fast track designation or I'm misinformed, as a shareholder, I hope I'm wrong and Ill be very happy to be corrected.